SMYD2

SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase that catalyzes the methylation of both histone and non-histone proteins, regulating chromatin accessibility and transcriptional activity^[1][2]. Mechanistically, SMYD2 facilitates signal transduction in key pathways, including BMP/SMAD, STAT3, and NF-κB, by methylating substrates such as BMPR2, STAT3, p65, and TRAF2^[3][4][5][6]. In disease models, aberrant SMYD2 expression drives tumor progression in triple-negative breast cancer, gastrointestinal cancers, and non-small-cell lung cancer, and contributes to vascular and renal pathologies, including neointimal hyperplasia and polycystic kidney disease^{[7][8][9][10]}. Compared with related isoforms such as SMYD1 and SMYD3, SMYD2 exhibits distinct substrate specificity and tissue distribution, showing cytoplasmic localization and preference for non-histone targets, which differentiates its regulatory roles^[1][2][11]. For experimental applications, selective chemical probes and inhibitors such as LLY-507, AZ505, A-893, and BAY-598 have enabled precise interrogation of SMYD2 functions in vitro and in vivo, suppressing methylation-dependent activation of oncogenic and inflammatory pathways^[6][12][13]. These inhibitors provide valuable tools for dissecting SMYD2-mediated epigenetic regulation and validating its therapeutic potential across multiple disease contexts^[12][13].